Our mission
Our mission is to develop innovative solutions that enable scientists to develop breakthrough nucleic acid-based therapies that improve human health.
Founding the company
Polyplus has been driven to innovate solutions for nucleic acid delivery that power your science since January 2001. Originally named Polyplus-transfection, the company shortened the name to Polyplus in 2022, as we began to expand our focus on building our portfolio of purpose fit solutions and services that help customers optimize upstream process economics.
Our Vision
Our vision is to help drug developers and manufacturers innovate with greater confidence and quality while reducing cost and time to market for cell and gene therapies and RNA & DNA therapeutics.
Our Management Team
Mario Philips draws on more than 20 years of scientific expertise, technical innovation, and operational management to lead the team in his role as CEO & Chairman at Polyplus. He has been an active industry advocate throughout his career, driving a great deal of progress in the single use space, and is now leading the charge to optimize upstream process economics for today’s advanced modalities.
Patrick Erbacher (Ph.D.) is a legacy Polyplus employee who joined as a postdoctoral research scientist working in founder, Dr. Behr’s, laboratory of genetic chemistry. During his time at the company, he has invaluably driven scientific strategy, and is a frequent author and inventor with 12 co-authored patent applications and more than 35 scientific publications.
Roel Gordijn has deep expertise in global commercial structure and operations in this evolving industry. He is responsible for building and driving commercial activity with a focus on what the customer is facing while working to accommodate the growing list of modalities in the market.
Chantal Devin-Chaloin (Ph.D.) joined the company with the goal of expanding and securing the global supply chain for Polyplus, customers and partners. She pulls from operations management experience in the contract space to help refine the go to market strategy and customer experience.
Stéphane Béchot joined Polyplus to manage Finance, Administration, IT. His expertise in Financial Consulting, Food industry, Engineering and IT Services have been a great resource to keep the company running efficiently.
Our Corporate Social Responsibility
Ethical
Responsible waste management
We consider our impact on the environment in the footprint of our facilities, how they are operated and the waste produced. New construction is focused on leveraging sustainable resources and minimizing wasteful output. All facilities have functional hazardous waste recovered as energy and non-hazardous waste recycled as materials.
Environment
Responsible use of resources
Our sustainability efforts are integrated into daily operations, including eco-friendly behavior training to align with our waste initiatives. We follow government energy-saving guidelines by setting temperatures to 19C in winter and 26C in summer. And decarbonated energy from predominantly nuclear resources powers our facilities.
Economic
Responsible jobs provider
It is our responsibility as an employer to offer quality jobs that empower individuals AND the communities we are located in. We prioritize making positive long-term impacts with sustainable design and leveraging alternative energy sources. As business models change, we are also decreasing our footprint in transportation, and via hybrid working models.
Research & Development
Based on its core know-how in the field of nucleic acid engineering and delivery technology, Polyplus ®’s R&D team is focused on developing innovative products for the upstream manufacturing of biologics for advanced medicinal therapy and for the development of nucleic acid-based therapeutics. Our R&D is optimizing key critical components of the manufacturing workflow (plasmids, media, transfection reagents) to increase viral vector titers and quality. Our R&D team is developing also critical materials (plasmids, lipids, polymers) and nanoparticle solutions for novel non-viral RNA/DNA therapeutics.
